1 Overactive Bladder (OAB) Therapeutics Market Overview 1.1 Product Overview and Scope of Overactive Bladder (OAB) Therapeutics 1.2 Overactive Bladder (OAB) Therapeutics Segment by Type 1.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Growth Rate Comparison by Type (2022-2028) 1.2.2 Anticholinergic Agents 1.2.3 Beta-3 Adrenoreceptor Agonists 1.3 Overactive Bladder (OAB) Therapeutics Segment by Application 1.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Comparison by Application: (2022-2028) 1.3.2 Hosptial 1.3.3 Clinci 1.3.4 Other 1.4 Global Overactive Bladder (OAB) Therapeutics Market Size Estimates and Forecasts 1.4.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2017-2028 1.4.2 Global Overactive Bladder (OAB) Therapeutics Sales 2017-2028 1.4.3 Overactive Bladder (OAB) Therapeutics Market Size by Region: 2017 Versus 2021 Versus 2028 2 Overactive Bladder (OAB) Therapeutics Market Competition by Manufacturers 2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2017-2022) 2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2017-2022) 2.3 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2017-2022) 2.4 Manufacturers Overactive Bladder (OAB) Therapeutics Manufacturing Sites, Area Served, Product Type 2.5 Overactive Bladder (OAB) Therapeutics Market Competitive Situation and Trends 2.5.1 Overactive Bladder (OAB) Therapeutics Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue 2.5.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario by Region 3.1 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Sales by Region: 2017-2022 3.2 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Revenue by Region: 2017-2022 3.3 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 3.3.1 North America Overactive Bladder (OAB) Therapeutics Sales by Country 3.3.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 3.4.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Country 3.4.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Region 3.5.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region 3.5.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 3.6.1 Latin America Overactive Bladder (OAB) Therapeutics Sales by Country 3.6.2 Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country 3.7.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country 3.7.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Overactive Bladder (OAB) Therapeutics Historic Market Analysis by Type 4.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2017-2022) 4.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2017-2022) 4.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2017-2022) 5 Global Overactive Bladder (OAB) Therapeutics Historic Market Analysis by Application 5.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2017-2022) 5.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2017-2022) 5.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2017-2022) 6 Key Companies Profiled 6.1 Allergan 6.1.1 Allergan Corporation Information 6.1.2 Allergan Description and Business Overview 6.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio 6.1.5 Allergan Recent Developments/Updates 6.2 Astellas Pharma 6.2.1 Astellas Pharma Corporation Information 6.2.2 Astellas Pharma Description and Business Overview 6.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio 6.2.5 Astellas Pharma Recent Developments/Updates 6.3 Hisamitsu Pharmaceutical 6.3.1 Hisamitsu Pharmaceutical Corporation Information 6.3.2 Hisamitsu Pharmaceutical Description and Business Overview 6.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio 6.3.5 Hisamitsu Pharmaceutical Recent Developments/Updates 6.4 Pfizer 6.4.1 Pfizer Corporation Information 6.4.2 Pfizer Description and Business Overview 6.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio 6.4.5 Pfizer Recent Developments/Updates 6.5 Ferring 6.5.1 Ferring Corporation Information 6.5.2 Ferring Description and Business Overview 6.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.5.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio 6.5.5 Ferring Recent Developments/Updates 6.6 GlaxoSmithKline 6.6.1 GlaxoSmithKline Corporation Information 6.6.2 GlaxoSmithKline Description and Business Overview 6.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio 6.6.5 GlaxoSmithKline Recent Developments/Updates 6.7 Ion Channel Innovations 6.6.1 Ion Channel Innovations Corporation Information 6.6.2 Ion Channel Innovations Description and Business Overview 6.6.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio 6.7.5 Ion Channel Innovations Recent Developments/Updates 6.8 Kwang Dong Pharmaceutical 6.8.1 Kwang Dong Pharmaceutical Corporation Information 6.8.2 Kwang Dong Pharmaceutical Description and Business Overview 6.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio 6.8.5 Kwang Dong Pharmaceutical Recent Developments/Updates 6.9 Lanzhou Institute of Biological Products 6.9.1 Lanzhou Institute of Biological Products Corporation Information 6.9.2 Lanzhou Institute of Biological Products Description and Business Overview 6.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio 6.9.5 Lanzhou Institute of Biological Products Recent Developments/Updates 6.10 Merck 6.10.1 Merck Corporation Information 6.10.2 Merck Description and Business Overview 6.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.10.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio 6.10.5 Merck Recent Developments/Updates 6.11 ONO Pharmaceutical 6.11.1 ONO Pharmaceutical Corporation Information 6.11.2 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Description and Business Overview 6.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio 6.11.5 ONO Pharmaceutical Recent Developments/Updates 6.12 Sanofi 6.12.1 Sanofi Corporation Information 6.12.2 Sanofi Overactive Bladder (OAB) Therapeutics Description and Business Overview 6.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio 6.12.5 Sanofi Recent Developments/Updates 6.13 Tengion 6.13.1 Tengion Corporation Information 6.13.2 Tengion Overactive Bladder (OAB) Therapeutics Description and Business Overview 6.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.13.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio 6.13.5 Tengion Recent Developments/Updates 6.14 Teva Pharmaceutical Industries 6.14.1 Teva Pharmaceutical Industries Corporation Information 6.14.2 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Description and Business Overview 6.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2017-2022) 6.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio 6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates 7 Overactive Bladder (OAB) Therapeutics Manufacturing Cost Analysis 7.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Overactive Bladder (OAB) Therapeutics 7.4 Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Overactive Bladder (OAB) Therapeutics Distributors List 8.3 Overactive Bladder (OAB) Therapeutics Customers 9 Overactive Bladder (OAB) Therapeutics Market Dynamics 9.1 Overactive Bladder (OAB) Therapeutics Industry Trends 9.2 Overactive Bladder (OAB) Therapeutics Market Drivers 9.3 Overactive Bladder (OAB) Therapeutics Market Challenges 9.4 Overactive Bladder (OAB) Therapeutics Market Restraints 10 Global Market Forecast 10.1 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Overactive Bladder (OAB) Therapeutics by Type (2023-2028) 10.1.2 Global Forecasted Revenue of Overactive Bladder (OAB) Therapeutics by Type (2023-2028) 10.2 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Overactive Bladder (OAB) Therapeutics by Application (2023-2028) 10.2.2 Global Forecasted Revenue of Overactive Bladder (OAB) Therapeutics by Application (2023-2028) 10.3 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Overactive Bladder (OAB) Therapeutics by Region (2023-2028) 10.3.2 Global Forecasted Revenue of Overactive Bladder (OAB) Therapeutics by Region (2023-2028) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Overactive Bladder (OAB) Therapeutics Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million) Table 2. Global Overactive Bladder (OAB) Therapeutics Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million) Table 3. Global Overactive Bladder (OAB) Therapeutics Market Size by Region (US$ Million) (2017 VS 2021 VS 2028) Table 4. Global Overactive Bladder (OAB) Therapeutics Market Competitive Situation by Manufacturers in 2021 Table 5. Global Overactive Bladder (OAB) Therapeutics Sales (K Units) of Key Manufacturers (2017-2022) Table 6. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2017-2022) Table 7. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Manufacturers (2017-2022) Table 8. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2017-2022) Table 9. Global Market Overactive Bladder (OAB) Therapeutics Average Price (USD/Unit) of Key Manufacturers (2017-2022) Table 10. Manufacturers Overactive Bladder (OAB) Therapeutics Manufacturing Sites and Area Served Table 11. Manufacturers Overactive Bladder (OAB) Therapeutics Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Overactive Bladder (OAB) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2021) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2017-2022) & (K Units) Table 16. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2017-2022) Table 17. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2017-2022) & (US$ Million) Table 18. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2017-2022) Table 19. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2017-2022) & (K Units) Table 20. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2017-2022) Table 21. North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2017-2022) & (US$ Million) Table 22. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2017-2022) Table 23. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2017-2022) & (K Units) Table 24. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2017-2022) Table 25. Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2017-2022) & (US$ Million) Table 26. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2017-2022) Table 27. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2017-2022) & (K Units) Table 28. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2017-2022) Table 29. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region (2017-2022) & (US$ Million) Table 30. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2017-2022) Table 31. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2017-2022) & (K Units) Table 32. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2017-2022) Table 33. Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country (2017-2022) & (US$ Million) Table 34. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2017-2022) Table 35. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2017-2022) & (K Units) Table 36. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2017-2022) Table 37. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2017-2022) & (US$ Million) Table 38. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2017-2022) Table 39. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2017-2022) & (K Units) Table 40. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2017-2022) Table 41. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2017-2022) & (US$ Million) Table 42. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2017-2022) Table 43. Global Overactive Bladder (OAB) Therapeutics Price by Type (2017-2022) & (USD/Unit) Table 44. Global Overactive Bladder (OAB) Therapeutics Sales (K Units) by Application (2017-2022) Table 45. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2017-2022) Table 46. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2017-2022) & (US$ Million) Table 47. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2017-2022) Table 48. Global Overactive Bladder (OAB) Therapeutics Price by Application (2017-2022) & (USD/Unit) Table 49. Allergan Corporation Information Table 50. Allergan Description and Business Overview Table 51. Allergan Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 52. Allergan Overactive Bladder (OAB) Therapeutics Product Table 53. Allergan Recent Developments/Updates Table 54. Astellas Pharma Corporation Information Table 55. Astellas Pharma Description and Business Overview Table 56. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 57. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Table 58. Astellas Pharma Recent Developments/Updates Table 59. Hisamitsu Pharmaceutical Corporation Information Table 60. Hisamitsu Pharmaceutical Description and Business Overview Table 61. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 62. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Table 63. Hisamitsu Pharmaceutical Recent Developments/Updates Table 64. Pfizer Corporation Information Table 65. Pfizer Description and Business Overview Table 66. Pfizer Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 67. Pfizer Overactive Bladder (OAB) Therapeutics Product Table 68. Pfizer Recent Developments/Updates Table 69. Ferring Corporation Information Table 70. Ferring Description and Business Overview Table 71. Ferring Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 72. Ferring Overactive Bladder (OAB) Therapeutics Product Table 73. Ferring Recent Developments/Updates Table 74. GlaxoSmithKline Corporation Information Table 75. GlaxoSmithKline Description and Business Overview Table 76. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 77. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Table 78. GlaxoSmithKline Recent Developments/Updates Table 79. Ion Channel Innovations Corporation Information Table 80. Ion Channel Innovations Description and Business Overview Table 81. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 82. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Table 83. Ion Channel Innovations Recent Developments/Updates Table 84. Kwang Dong Pharmaceutical Corporation Information Table 85. Kwang Dong Pharmaceutical Description and Business Overview Table 86. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 87. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Table 88. Kwang Dong Pharmaceutical Recent Developments/Updates Table 89. Lanzhou Institute of Biological Products Corporation Information Table 90. Lanzhou Institute of Biological Products Description and Business Overview Table 91. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 92. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Table 93. Lanzhou Institute of Biological Products Recent Developments/Updates Table 94. Merck Corporation Information Table 95. Merck Description and Business Overview Table 96. Merck Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 97. Merck Overactive Bladder (OAB) Therapeutics Product Table 98. Merck Recent Developments/Updates Table 99. ONO Pharmaceutical Corporation Information Table 100. ONO Pharmaceutical Description and Business Overview Table 101. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 102. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Table 103. ONO Pharmaceutical Recent Developments/Updates Table 104. Sanofi Corporation Information Table 105. Sanofi Description and Business Overview Table 106. Sanofi Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 107. Sanofi Overactive Bladder (OAB) Therapeutics Product Table 108. Sanofi Recent Developments/Updates Table 109. Tengion Corporation Information Table 110. Tengion Description and Business Overview Table 111. Tengion Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 112. Tengion Overactive Bladder (OAB) Therapeutics Product Table 113. Tengion Recent Developments/Updates Table 114. Teva Pharmaceutical Industries Corporation Information Table 115. Teva Pharmaceutical Industries Description and Business Overview Table 116. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 117. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Table 118. Teva Pharmaceutical Industries Recent Developments/Updates Table 119. Production Base and Market Concentration Rate of Raw Material Table 120. Key Suppliers of Raw Materials Table 121. Overactive Bladder (OAB) Therapeutics Distributors List Table 122. Overactive Bladder (OAB) Therapeutics Customers List Table 123. Overactive Bladder (OAB) Therapeutics Market Trends Table 124. Overactive Bladder (OAB) Therapeutics Market Drivers Table 125. Overactive Bladder (OAB) Therapeutics Market Challenges Table 126. Overactive Bladder (OAB) Therapeutics Market Restraints Table 127. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2023-2028) & (K Units) Table 128. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Type (2023-2028) Table 129. Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Type (2023-2028) & (US$ Million) Table 130. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Type (2023-2028) Table 131. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2023-2028) & (K Units) Table 132. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Application (2023-2028) Table 133. Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Application (2023-2028) & (US$ Million) Table 134. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Application (2023-2028) Table 135. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Region (2023-2028) & (K Units) Table 136. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Region (2023-2028) Table 137. Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Region (2023-2028) & (US$ Million) Table 138. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Region (2023-2028) Table 139. Research Programs/Design for This Report Table 140. Key Data Information from Secondary Sources Table 141. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Overactive Bladder (OAB) Therapeutics Figure 2. Global Overactive Bladder (OAB) Therapeutics Market Share by Type in 2021 & 2028 Figure 3. Anticholinergic Agents Product Picture Figure 4. Beta-3 Adrenoreceptor Agonists Product Picture Figure 5. Global Overactive Bladder (OAB) Therapeutics Market Share by Application in 2021 & 2028 Figure 6. Hosptial Figure 7. Clinci Figure 8. Other Figure 9. Global Overactive Bladder (OAB) Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 10. Global Overactive Bladder (OAB) Therapeutics Market Size (2017-2028) & (US$ Million) Figure 11. Global Overactive Bladder (OAB) Therapeutics Sales (2017-2028) & (K Units) Figure 12. Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers in 2021 Figure 13. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers in 2021 Figure 14. The Global 5 and 10 Largest Overactive Bladder (OAB) Therapeutics Players: Market Share by Revenue in 2021 Figure 15. Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 16. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2017-2022) Figure 17. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2021 Figure 18. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2017-2022) Figure 19. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region in 2021 Figure 20. U.S. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 21. Canada Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 22. Germany Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 23. France Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 24. U.K. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 25. Italy Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 26. Russia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 27. China Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 28. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 29. South Korea Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 30. India Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 31. Australia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 32. Taiwan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 33. Indonesia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 34. Thailand Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 35. Malaysia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 36. Philippines Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 37. Vietnam Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 38. Mexico Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 39. Brazil Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 40. Argentina Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 41. Turkey Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 42. Saudi Arabia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 43. U.A.E Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million) Figure 44. Sales Market Share of Overactive Bladder (OAB) Therapeutics by Type (2017-2022) Figure 45. Manufacturing Cost Structure of Overactive Bladder (OAB) Therapeutics Figure 46. Manufacturing Process Analysis of Overactive Bladder (OAB) Therapeutics Figure 47. Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis Figure 48. Channels of Distribution Figure 49. Distributors Profiles Figure 50. Bottom-up and Top-down Approaches for This Report Figure 51. Data Triangulation Figure 52. Key Executives Interviewed

Allergan Astellas Pharma Hisamitsu Pharmaceutical Pfizer Ferring GlaxoSmithKline Ion Channel Innovations Kwang Dong Pharmaceutical Lanzhou Institute of Biological Products Merck ONO Pharmaceutical Sanofi Tengion Teva Pharmaceutical Industries